Skip to main content

Table 2 Differences between SARS-CoV-2 pneumonia patterns: unilateral and bilateral

From: Clinical characteristics of SARS-CoV-2 pneumonia diagnosed in a primary care practice in Madrid (Spain)

Pneumonia

Unilateral

Bilateral

p-value

Number (%)

46 (26.7)

126 (73.3)

 

Pneumonia onset, mean (SD), days

8.2 (5.1)

7.7 (3.7)

0.47

Sociodemographic variables

 Age, mean (SD), years

53.7 (16.6)

63.0 (16.6)

 

 Sex, n (%)

  Female

28 (60.9)

59 (46.8)

0.10

  Male

18 (39.1)

67 (53.2)

0.10

Comorbidities

 Cardiovascular risk factor

  Smoke habit, n (%)

4 (8.7)

9 (7.1)

0.38

  BMI ≥ 25 kg/m2, n (%)

20 (43.5)

70 (55.6)

0.25

  Hypertension, n (%)

16 (34.8)

67 (53.2)

0.033

  type 2 Diabetes, n (%)

4 (8.7)

29 (23.0)

0.035

  Dyslipidemia, n (%)

15 (32.6)

53 (42.1)

0.26

 Respiratory diseases

  Asthma, n (%)

4 (8.7)

17 (13.5)

0.40

  COPD, n (%)

3 (6.5)

6 (4.8)

0.65

 Cardiovascular diseases

  Ischaemic heart diseases, n (%)

1 (2.2)

8 (6.3)

0.28

  Arrhythmias, n (%)

1 (2.2)

9 (7.1)

0.22

  Heart failure, n (%)

2 (4.3)

5 (4.0)

0.91

Other diseases

  Chronic kidney diseases, n (%)

0 (0.0)

12 (9.5)

0.030

  Cognitive impairment, n (%)

3 (6.5)

7 (5.6)

0.81

  Cancer, n (%)

1 (2.2)

9 (7.1)

0.22

  Rheumatological diseases, n (%)

2 (4.3)

12 (9.5)

0.27

Chronic treatment

 no drugs, n (%)

8 (17.4)

25 (19.8)

0.60

 1–4 drugs, n (%)

21 (45.7)

47 (37.3)

 

 5–9 drugs, n (%)

12 (26.1)

31 (24.6)

 

 ≥ 10 drugs, n (%)

5 (10.9)

23 (18.3)

 

 Antithrombotic/anticoagulant treatment

  Antithrombotic drug, n (%)

1 (2.2)

13 (10.3)

0.22

  Anticoagulant drug, n (%)

2 (4.3)

6 (4.8)

 

  Non consumption, n (%)

43 (93.5)

107 (84.9)

 

Symptoms

 Fever, n (%)

38 (82.6)

106 (84.1)

0.81

 Cough, n (%)

37 (80.4)

103 (81.7)

0.84

 Dyspnea, n (%)

24 (52.2)

79 (62.7)

0.21

 Gastrointestinal disturbances, n(%)

18 (39.1)

54(42.9)

0.66

 Myalgias, n (%)

17 (37.0)

34 (27.0)

0.20

 Thoracic Pain, n (%)

10 (21.7)

17 (13.5)

0.19

 Pleural chest Pain, n (%)

6 (13.0)

4 (3.2)

0.014

 Rhinitis, n (%)

4 (8.7)

4 (3.2)

0.13

 Odynophagia, n (%)

7 (15.2)

13 (10.3)

0.37

 Asthenia, n (%)

12 (26.1)

35 (27.8)

0.83

 Headache, n (%)

12 (26.1)

35 (27.8)

0.83

 Dysgeusia, n (%)

3 (6.5)

6 (4.8)

0.65

 Anosmia, n (%)

1 (2.2)

1 (0.8)

0.45

Symptoms categorized

 1–3 total symptoms, n (%)

25 (54.3)

72 (57.6)

0.70

 ≥ 4 total symptoms, n (%)

21 (45.7)

53 (42.4)

 

Physical examination

 Temperature, mean (SD), ºC

37.2 (0.8)

37.3 (0.8)

0.86

 Heart rate, mean (SD), bpm

96.2 (15.1)

92.2 (16.4)

0.20

 Respiratory rate, median (IQR), rpm

16.0 (14.0, 16.0)

17.0 (15.0, 22.0)

0.073

 Pulse oximetry, median (IQR), %

96.0 (94.0, 97.0)

94.0 (91.0, 96.0)

 < 0.001

 Normal lung auscultation, n (%)

16 (34.8)

22 (17.5)

0.014

 Abnormal lung auscultation, n (%)

8 (17.4)

46 (36.5)

0.014

Blood test

 CRP, median (IQR), mg/L

29.6 (5.0, 81.5)

81.5 (46.2, 143.0)

 < 0.001

 Lymphocytes, median (IQR), 10e3/ml

1400.0 (1100.0, 1880.0)

1000.0 (800.0, 1400.0)

 < 0.001

 D-Dimer, median (IQR), μg/L

339.0 (197.0, 464.0)

520.0 (320.0, 1030.0)

0.035

 Fibrinogen ≥ 500, n (%), mg/dL

24 (52.2)

103 (81.7)

 < 0.001

 Ferritin, median (IQR), μg/L

618.0 (280.5, 919.0)

424.0 (200.0, 1215.0)

0.96

RT-PCR SARS-CoV-2

 Negative, n (%)

17 (37.0)

19 (15.1)

0.006

 Positive, n (%)

25 (54.3)

97 (77.0)

 

Complications

 Hospital admission, n (%)

20 (43.5)

120 (95.2)

 < 0.001

 Pulmonary thromboembolism, n (%)

0 (0.0)

7 (5.6)

0.10

 Death, n (%)

1 (2.2)

10 (7.9)

0.17

  1. n number, SD standard deviation, BMI body mass index, COPD chronic obstructive pulmonary disease, IQR interquartile range, CRP C-reactive protein, RT-PCR reverse transcription PCR, bpm beats per minute, rpm respiratory rate per minute